MiMedx Group, Inc. (MDXG)
6.98
0.00 (0.00%)
USD |
NASDAQ |
Dec 10, 16:00
6.985
0.00 (0.00%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.034B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -28.41% |
| Valuation | |
| PE Ratio | 25.57 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.652 |
| Price to Book Value | 4.326 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0762 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 85.36% |
Profile
| MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA. |
| URL | http://www.mimedx.com |
| Investor Relations URL | https://mimedx.gcs-web.com |
| HQ State/Province | Georgia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Oct. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA. |
| URL | http://www.mimedx.com |
| Investor Relations URL | https://mimedx.gcs-web.com |
| HQ State/Province | Georgia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Oct. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |